Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100en_US
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorYıldırım, Hasan Çağrı
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorAktepe, Oktay Halit
dc.contributor.authorTaban, Hakan
dc.contributor.authorYılmaz, Feride
dc.contributor.authorYaşar, Serkan
dc.contributor.authorAktaş, Burak Yasin
dc.contributor.authorGüner, Gürkan
dc.contributor.authorDizdar, Ömer
dc.contributor.authorAksoy, Sercan
dc.contributor.authorErman, Mustafa
dc.contributor.authorYalçın, Suayib
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2022-04-11T11:37:14Z
dc.date.available2022-04-11T11:37:14Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractObjectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate HPD and PD. Methods: Ninety-five patients treated with ICIs with progression according to response evaluation criteria ın solid tumors criteria in the first control imaging were included. HPD was defined according to Russo's work. The PILE scoring system, which includes pan-immune-inflammation value, lactate dehydrogenase, and Eastern Cooperative Oncology Group PS, was followed. The relationship between PILE score and HPD was analyzed. Results: The median OS of all cohorts was 11.18 months. The patients in the HPD group had decreased OS (4.77 vs. 13.94 months, p<0.001) and progression-free survival (PFS) (1.89 vs. 3.16 months, p<0.001) compared with those in the PD group. The risk of HPD was higher than the risk of PD in patients with a high PILE score (p=0.001). Conclusion: In this study, we showed that patients treated with ICI with a higher PILE score are at greater risk for HPD. The PILE score may be a biomarker to differentiate HPD from PD. © 2022 by Eurasian Journal of Medicine and Oncology.en_US
dc.identifier.citationYildirim, H. C., Guven, D. C., Aktepe, O. H., Taban, H., Yilmaz, F., Yasar, S., ... & Kilickap, S. (2022). Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy.en_US
dc.identifier.doi10.14744/ejmo.2022.78280en_US
dc.identifier.endpage63en_US
dc.identifier.issn2587-2400en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85127198775en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage59en_US
dc.identifier.urihttps://doi.org/10.14744/ejmo.2022.78280
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2636
dc.identifier.volume6en_US
dc.identifier.wosWOS:000820473900008en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherKare Publishingen_US
dc.relation.ispartofEurasian Journal of Medicine and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHyperprogressive Diseaseen_US
dc.subjectImmun Checkpoint Inhibitorsen_US
dc.subjectImmunotherapyen_US
dc.subjectPILE Scoreen_US
dc.titleDifferences between hyperprogressive disease and progressive disease in patients receiving immunotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
212.pdf
Boyut:
207.27 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu